
Cooper Companies (COO) Stock Forecast & Price Target
Cooper Companies (COO) Analyst Ratings
Bulls say
Cooper Companies is well positioned by its leadership in eyecare and women’s health, with CooperVision commanding roughly one fourth of the US contact lens market and CooperSurgical holding the broadest medical device coverage across the IVF cycle plus 17% of the US IUD market. Fundamental support also comes from solid operating execution, including F2Q26 revenue of $1.082B and adjusted EPS of $1.21, both ahead of consensus, while operating margin expanded to 26.3% and free cash flow guidance was raised to $650M. The outlook is further strengthened by management’s strategic review, increased share repurchase authorization to $3B, and evidence of improving CSI growth and fertility trends that could unlock additional value.
Bears say
Cooper Companies is facing a weak fundamental setup as F3Q26 revenue of $1.066B missed consensus and adjusted EPS of $1.15 only matched after tariff refunds, while management cut FY26 revenue guidance to $4.229B-$4.252B and EPS to $4.51-$4.55. CooperVision is the main drag, with 0% organic growth, US channel inventory de-stocking, and an estimated 110 bps of share loss, while APAC weakness and softer legacy hydrogel demand add pressure to an already slowing contact lens franchise. CooperSurgical also decelerated to 3% organic growth, and with FY27 tax rate rising to 17.5% plus heavier commercial investment, EPS growth appears set to slow further.
This aggregate rating is based on analysts' research of Cooper Companies and is not a guaranteed prediction by Public.com or investment advice.
Cooper Companies (COO) Analyst Forecast & Price Prediction
Start investing in Cooper Companies (COO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Cooper Companies (COO) Forecast
Cooper Companies (COO) Analyst Forecast & Price Prediction
Start investing in Cooper Companies (COO)
Order type
Buy in
Order amount
Est. shares
0 shares